The Institute of Genetics and Cytology offers consumers services for assessing the risk of miscarriage using a DNA testing system for women with disorders of the physiological course of pregnancy under an outsourcing agreement and is looking for partners to develop a DNA testing system under a distribution services agreement.

A technology has been developed to assess the risk of miscarriage by genetic markers associated, including
including, with an increased tendency to thrombosis.

Every year, every fifth desired pregnancy ends in a spontaneous abortion (according to the Ministry of Health of the Russian Federation). Recently, one of the main causes of miscarriages has been considered hereditary thrombophilia, in which the tendency to intravascular thrombosis is increased. determine genetic predisposition thrombophilia is possible only with the help of DNA analysis. The genetic risk of thrombophilia is often realized only under additional conditions, in particular during pregnancy. At the same time, clinical and biochemical analyzes before pregnancy do not reveal abnormalities, but with the development of pregnancy, microthrombi are formed in the placenta that clog the umbilical cord, and spontaneous miscarriage occurs or the development of pregnancy stops (“frozen” pregnancy).

Molecular genetic analysis allows you to identify the presence of risk factors for pregnancy disorders in each case. in the genotypes of 90.7% of the women examined by us with habitual miscarriages, from 3 to 6 risk factors for miscarriage, more than a third of patients (35%) had 5 of these in the genotype factors.

Modern medical science has the means and methods for correcting adverse manifestations hereditary information. With a high risk of pregnancy loss, the gynecologist prescribes medicinal drugs that correct the effects of unfavorable gene variants, which ensures the normal course of pregnancy. Our survey of 1000 patients with established genetic causes of miscarriage and receiving appropriate medications showed successful birth of children in 86.6% of cases.

More details in the Catalog of the Institute of Genetics and Cytology "Applied Developments".

International certificate of the reference institute of bioanalytics (Bonn, Germany) dated 08.04.2017

Unfavorable gene variants are identified, the effects of which are corrected by physicians with the help of antithrombotic agents and folic acid preparations. This contributes to the successful completion of pregnancy.

Main areas of research:

– Study of the structural and functional organization of the genomes of plants, animals, humans and microorganisms;
– Studying the problems of genetic and cellular engineering;
– Development of genetic bases for breeding plants, animals and microorganisms;
– Creation of genomic technologies for agriculture, healthcare, sports, environmental protection;
– Study of biosafety issues;
– Provision of services for DNA marking and DNA certification of plants, animals, humans and microorganisms;
– Collection and preservation of unique DNA samples as sources of valuable genetic information;
– Monitoring of the genetic resources of the Republic of Belarus, promotion of access to genetic resources and benefit sharing;
– Provision of services for determining the content of genetically modified ingredients in food raw materials and food products.

International agreements on scientific partnership have been concluded with the Medical Genetic Research Center (Russia), the Estonian Biocenter (Estonia), the Institute of Genetics and Animal Breeding of the Polish Academy of Sciences (Poland), the National Institute of Biology of the Republic of Slovenia (Slovenia, Institute of Plant Genetic Resources “K. Malkov”, Sadovo of Agricultural Academy (Bulgaria), Ivane Beritashvili Center for Experimental Biomedicine (Georgia), Institute of Molecular and Cellular Biology SB RAS (Russia), etc.

Consumers interested in purchasing miscarriage risk assessment services using a DNA testing system for women with physiological pregnancy disorders under an outsourcing agreement.

Partners interested in developing services for assessing the risk of miscarriage using a DNA testing system for women with violations of the physiological course of pregnancy under a distribution services agreement.